Skip to content
Evigrade
CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antidepressants. Other antidepressants of herbal origin

Updated · Methodology

Mechanism

Cobicistat inhibits the enzyme CYP3A and thereby raises the levels of atazanavir or darunavir, which it is taken with. CYP3A also clears cobicistat itself (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). St John's wort induces CYP3A4 and the transporter P-glycoprotein (St John's wort herbal monograph, EMA). The cobicistat documents list St John's wort among strong CYP3A inducers: cobicistat levels may fall, the levels of atazanavir or darunavir follow, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (cobicistat SmPC, EMA, and cobicistat label, US Food and Drug Administration, FDA). For the darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablet, St John's wort may also markedly lower tenofovir alafenamide levels through P-glycoprotein (SmPC of this product, EMA). The documents do not describe any effect of cobicistat on St John's wort.

Symptoms

The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. The Spanish SmPC of a St John's wort product also lists a fall in levels with possible loss of HIV suppression for atazanavir and darunavir (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. St John's wort is on the cobicistat contraindication list of strong CYP3A inducers, together with rifampicin, carbamazepine, phenobarbital and phenytoin (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with atazanavir, darunavir and elvitegravir (SmPCs of these products, EMA). The St John's wort documents do not name cobicistat. Still, the Spanish St John's wort product must not be taken with protease inhibitors, and its interaction table names atazanavir and darunavir, the drugs that cobicistat boosts (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The authorisation of this product has been suspended since June 2026, and there is no other current Spanish St John's wort SmPC. The EMA monograph contraindicates St John's wort with protease inhibitors for well-established use products, and for traditional use products when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA). The cobicistat documents make no such dose exception. Stop St John's wort before starting cobicistat (cobicistat SmPC, EMA, and FDA label). The increased enzyme activity returns to normal within 1 week after St John's wort is stopped (St John's wort herbal monograph, EMA), but the cobicistat documents give no exact interval before cobicistat is started. Before starting cobicistat and during treatment, consider possible interactions and review all concomitant medicines (cobicistat FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cobicistat

Other interactions with Hypericum perforatum